Application Note

Breaking the Barrier of KRAS^G12C Inhibitor Resistance: Developing KRAS^G12C Inhibitor-Resistant Tumor Models

KRAS^G12C inhibitors like sotorasib (AMG510) and adagrasib (MRTX849) have revolutionized cancer therapy by targeting the KRAS^G12C mutation, locking it in an inactive state to inhibit tumor growth. However, acquired resistance, driven by mutations such as G12D, Y96C, R68S, and Q61H, remains a significant hurdle, limiting long-term efficacy.

We’ve developed several resistance models to address this challenge:

• Pretreated PDX Models: From patient tumors resistant to KRAS^G12C inhibitors.
  
  
• Drug-Induced Resistant PDX Models: Generated in vivo to mimic resistance evolution.
  
  
• Gene-Engineered Resistant CDX Models: Using gene-modified cell lines.

Learn how these models can help advance and accelerate your drug development efforts by reading the full application note today.

Download The Application Note Now!